When European politicians voted overwhelmingly in favor of a clinical research data sharing law last month, it looked like a big step forward for transparency campaigners. Yet just weeks later researchers have raised concerns that the European Medicines Agency (EMA) is already trying to lessen the impact of the legislation.
These restrictions would limit researchers' ability to reanalyze the results. Tom Jefferson and Peter Doshi, two of the people who pressured Roche ($RHHBY) to share its data on Tamiflu, called the EMA's draft policy "a stunning and surprising reversal." The European ombudsman and other researchers have also criticized the document, with the former calling for the EMA to explain the reasons and legal basis for what she views as a significant change of policy.
The EMA has denied that its draft policy sets back the transparency agenda, with spokesperson Martin Harvey-Allchurch saying the document is intended to facilitate access. In the Science article, Harvey-Allchurch is the lone defender of the terms, although no members of the biopharma industry are quoted. Having lobbied against the transparency law, some of the restrictions--such as the ability to redact novel statistical or other analytical methods--are likely to be welcomed by the industry.
- read the ScienceInsider article
Industry Voices: Clinical trial transparency--time for some carrot as well as more stick?